CORONAVIRUS/Taiwanese team identifies 4 potential antiviral drugs for COVID-19

Taipei, Feb. 23 (CNA) A research team from a domestic university has identified four promising antiviral drug candidates that can inhibit the coronavirus that causes COVID-19, the team leader said Tuesday.
One of the drug candidates -- JMY206 -- is more than 10 times stronger than remdesivir, the first antiviral drug fully certified for the treatment of COVID-19 patients, said Yang Jinn-moon (楊進木), dean of College of Biological Science and Technology at National Yang Ming Chiao Tung University (NYCU), who led the research team.
The other drugs identified as being able to inhibit SARS-CoV-2, the virus that causes COVID-19, are boceprevir, an oral, direct acting hepatitis C virus (HCV) protease inhibitor; telaprevir, a hepatitis C drug; and nelfinavir, an antiretroviral drug used to treat human immunodeficiency virus (HIV), Yang said.
The team's starting point was its understanding that SARS-CoV-2 is highly similar to the virus that causes severe acute respiratory syndrome (SARS), Yang said.
It then gathered SARS-related data and screened U.S. Food and Drug Administration (FDA)-approved drugs and natural products for possible COVID-19 drug treatments, according to Yang.
By using artificial intelligence and big data, the team created simulations of changes in cell mechanisms after SARS-CoV-2 entered human host cells and compared them with 250 images published around the world of the three-dimensional architecture of the main protease of SARS-CoV-2.
That resulted in the identification of six possible structures of key proteases -- the enzymes that break down proteins and can lead to disease -- that are essential for promoting SARS-CoV-2 viral entry, Yang said.
By identifying these structures, the team then identified four types of drugs that could inhibit these proteases and consequently the virus.
The most potent, called JMY206, can inhibit the SARS-CoV-2 virus from entering the host cell and comes with a potency that is at least 10 times stronger than remdesivir.
The therapeutic benefits of JMY 206 have also been proven in animal experiments and it can be a potential oral drug against COVID-19, Yang said.
The team is applying to patent its discovery and planning to publish a paper on it and develop new medicines by combining other medicinal components.
- First batch of COVID-19 vaccine expected in Taiwan by April: premierA total of 4.76 million doses of COVID-19 vaccine Taiwan has secured through the global vaccine-sharing initiative COVAX are expected to become available by April, Premier Su ...02/26/2021 03:50 PM
- Taiwan reports 5 new imported cases of COVID-19Taiwan reported five new imported cases of COVID-19 on Thursday, all involving female migrant workers from the Philippines and bringing the total number to 951 since the pandemic ...02/25/2021 03:37 PM
- Swedish TV program profiles Taiwan's COVID-19 responseA Swedish television program which covers international affairs aired a new episode Tuesday examining Taiwan's successful response to the COVID-19 pandemic.02/24/2021 08:30 PM
- Society
Taiwan forecast to have stable weather during holiday
02/27/2021 12:24 PM - Society
Taiwan headline news
02/27/2021 11:53 AM - Culture
President Tsai celebrates Lantern Festival, eats 'tangyuan'
02/26/2021 10:47 PM - Culture
Two young Taiwanese receive art awards at Czech office in Taipei
02/26/2021 10:46 PM - Cross-Strait
Local officials lament China's halt of Taiwan pineapple imports
02/26/2021 09:52 PM